Ernexa Therapeutics (ERNAW) Accounts Payables (2010 - 2026)

Ernexa Therapeutics has reported Accounts Payables for 17 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 1.96% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 1.96% YoY), and the FY2025 full-year result was $1.1 million, down 34.63% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.3 million, up from $1.1 million in the prior quarter.
• The five-year high for Accounts Payables was $2.7 million in Q2 2023, with the low at $958000.0 in Q3 2025.
• Historically, Accounts Payables has averaged $1.5 million across 5 years, with a median of $1.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables slumped 59.83% — and 2023, when it jumped 80.99%.
• Ernexa Therapeutics' Accounts Payables stood at $1.6 million in 2022, then slumped by 34.14% to $1.1 million in 2023, then soared by 61.29% to $1.7 million in 2024, then slumped by 34.63% to $1.1 million in 2025, then climbed by 15.56% to $1.3 million in 2026.
• The last three Accounts Payables figures came in at $1.3 million (Q1 2026), $1.1 million (Q4 2025), and $958000.0 (Q3 2025), per Business Quant data.